The New England journal of medicine, 2017-08, Vol.377 (7), p.633-643
2017
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Cognitive Function in a Randomized Trial of Evolocumab
- Ist Teil von
- The New England journal of medicine, 2017-08, Vol.377 (7), p.633-643
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2017
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- To address concerns about cognitive decline with the use of PCSK9 inhibitors, automated neuropsychological testing was performed in patients who received evolocumab or placebo. Evolocumab was noninferior to placebo with respect to cognitive changes from baseline over 19 months.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1701131Titel-ID: cdi_cristin_nora_10852_63031
- Format
- –
- Schlagworte
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal - adverse effects, Antibodies, Monoclonal - therapeutic use, Antibodies, Monoclonal, Humanized, Anticholesteremic Agents - adverse effects, Anticholesteremic Agents - therapeutic use, Atherosclerosis - drug therapy, Atherosclerosis - psychology, Cholesterol, Cholesterol, LDL - blood, Clinical trials, Cognition & reasoning, Cognition - drug effects, Cognitive ability, Double-Blind Method, Drug Therapy, Combination, Evidence-based medicine, Executive function, Female, Health risk assessment, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use, Kexin, Low density lipoprotein, Male, Memory - drug effects, Middle Aged, Monoclonal antibodies, PCSK9 Inhibitors, Proprotein convertases, Prospective Studies, Psychological Tests, Self-Assessment, Short term memory, Spatial memory, Statins, Subtilisin